In the last few years, a great interest has emerged in investigating the pleiotropic effects of
Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower …

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as promising
therapeutic agents with potent anti-inflammatory properties and diverse clinical implications …

Type 2 diabetes mellitus (T2DM) is currently one of the most prevalent diseases, with as
many as 415 million patients worldwide. T2DM is characterized by elevated blood glucose …

Aim To conduct a meta‐analysis and systematic review to examine the effects of glucagon‐
like peptide‐1 receptor agonists (GLP‐1RAs) on clinical biomarkers of inflammation and …

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid hormone secreted by L cells in the
distal ileum, colon, and pancreatic α cells, which participates in blood sugar regulation by …

Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone mainly secreted from intestinal L
cells in response to nutrient ingestion. GLP‐1 has beneficial effects for glucose homeostasis …

Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD),
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …

Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose
metabolism and energy homeostasis through regulation of islet hormone secretion …

Glucagon and glucagon-like peptide-1 (GLP-1) are polypeptide hormones that are produced
by pancreatic α-cells and the intestine, respectively, whose main function is to control …